Aorto-iliac Occlusive Disease Treatment Market Size, Share, and Industry Analysis, By Product Type (Endovascular Devices {Balloon Catheters, Stents, Atherectomy Systems, and Others}, and Surgical Devices), By Procedure Type (Endovascular Procedures {Aorto-iliac Angioplasty (PTA), Aorto-iliac Stenting, Atherectomy-assisted Revascularization, and Others}, Hybrid Procedures, and Open Surgical Procedures), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast 2026-2034

The aorto iliac occlusive disease treatment market size was valued at USD 2.24 billion in 2025 and is expected to reach a market valuation of USD 2.36 billion in 2026. Furthermore, the market is projected to reach a market valuation of USD 3.56 billion by 2034, exhibiting a CAGR of 5.3% during the forecast period.

The market growth is attributed to the increasing shift toward endovascular procedures, such as iliac angioplasty and stenting, which reduce hospital stays, facilitate faster recovery, and are suitable for higher-risk surgical patients, thereby supporting higher procedure volumes.

Aorto iliac Occlusive Disease Treatment Market Driver

Rising Prevalence of Peripheral Artery Disease to Drive the Market Growth

In recent years, there has been an increasing prevalence of peripheral artery diseases due to risk factors such as diabetes, aging, smoking, hypertension, and dyslipidemia, which is increasing symptomatic aorto-iliac disease, expanding the treated population, and driving demand for devices. This is anticipated to drive market growth in the coming years.

• For instance, according to data published by the American College of Radiology in October 2024, peripheral artery disease affects 3-10% of adults in Western populations, while prevalence often exceeds 20% in Asia and other developing regions.

Download Free sample to learn more about this report.

According to data published by the Population Reference Bureau (PRB), the U.S. population aged 65 and older is expected to grow from 58.0 million in 2022 to 82.0 million by 2050.

Aorto-iliac Occlusive Disease Treatment Market Restraint

High Total Procedure Cost and Reimbursement Variability to Hamper the Market Growth

In several countries, the cost of key procedures, including aorto-iliac angioplasty (PTA), is high. Also, device-intensive cases can face reimbursement pressure, which is expected to slow down the adoption in cost-sensitive systems. Such a scenario is anticipated to hamper the market expansion over the forecast period.

Aorto-iliac Occlusive Disease Treatment Market Opportunity

Expansion in Emerging Markets and Outpatient Settings to Offer Lucrative Growth Opportunity

In recent years, there has been an expansion in healthcare infrastructure, hospital capacities, trained interventionists, and migration of suitable cases to outpatient settings, which is driving procedure volume and improving access. This represents a lucrative opportunity for key players to expand product offerings in emerging economies.

• For instance, the Union Budget 2025-26 boosts healthcare infrastructure with a higher allocation of USD 465 million for the Ministry of Ayush.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Conditions, by Countries/Region, 2025
• Technological Advancements in Aorto-iliac Occlusive Disease Treatment Devices
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Product Type

By product type, the market is segmented into endovascular devices and surgical devices. The endovascular devices are further sub-segmented into balloon catheters, stents, atherectomy systems, and others.

The endovascular devices segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is driven by increased stent use in Iliac artery disease and other indications, prompting key players to expand their product availability.

Analysis by Procedure Type

By procedure type, the market is segmented into endovascular procedures, hybrid procedures, and open surgical procedures. The endovascular procedures is further sub-segmented into aorto-iliac angioplasty (PTA), aorto-iliac stenting, atherectomy-assisted revascularization, and others.

The endovascular procedures segment is expected to hold the major share of the global market during the forecast period. The growth is attributed to the increasing number of endovascular procedures, driven by shorter hospital stays and lower perioperative morbidity, which make them suitable for elderly individuals.

Analysis by End-user

Based on end-user, the market is divided into hospitals & ASCs, specialty clinics, and others.

The hospitals & ASCs segment is expected to hold the largest share of the global market during the forecast period. The segment’s growth is attributed to these settings' capabilities in complex case handling and access to hybrid ORs & advanced imaging. Moreover, a large number of hospitals in developed countries is anticipated to favor the utilization of aorto-iliac occlusive disease treatment devices.

• For instance, the 2026 American Hospital Association (AHA) data report indicates around 6,100 hospitals across the U.S.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 42.4% share of the global aorto-iliac occlusive disease treatment market in 2025. The growth is attributed to strong adoption of endovascular-first strategies and favorable reimbursement for iliac stenting and covered stents in the region.

• For instance, the U.S. Centers for Medicare & Medicaid Services' CPT code 37221 describes the revascularization of the iliac artery via stent placement.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region’s growth is attributed to increased awareness and screening for PAD, as well as the growing adoption of minimally invasive procedures in countries such as India, China, and others.

Key Players Covered

The global market for aorto-iliac occlusive disease treatment is highly fragmented, with major players pursuing partnerships and distribution deals to broaden their worldwide presence.

The report includes the profiles of the following key players:

• Abbott (U.S.)
• L. Gore & Associates, Inc. (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Cordis (U.S.)
• Cook (U.S.)
• BIOTRONIK (Germany)
• Getinge (Sweden)
• LeMaitre Vascular (U.S.)
• BD (U.S.)

Key Industry Developments

• May 2025: Boston Scientific Corporation began the ORION clinical trial to evaluate its next-generation EPIC self-expanding nitinol stent system for treating iliac artery disease.
• March 2025: Boston Scientific received FDA approval for its Express LD Iliac Stent System, the first low-profile, premounted, balloon-expandable stent for treating iliac artery disease.